Not Yet RecruitingNot Applicable

One Year Results of Managing Primary Spondylodiscitis

50 participantsStarted 2026-05

Plain-language summary

Primary spondylodiscitis is a severe infectious condition involving the spinal discs and adjacent vertebrae. It often causes significant back pain and requires careful management, typically involving long-term antibiotics and spinal braces, or surgery in more complex cases. The purpose of this observational study is to evaluate the one-year clinical and surgical outcomes of patients receiving standard-of-care treatment for primary spondylodiscitis at Assiut University Hospital. The study aims to enroll approximately 50 patients. Researchers will follow these participants prospectively for one year from the start of their treatment. During this time, patients will undergo regular clinical evaluations, laboratory blood tests (such as CRP and ESR to monitor infection and inflammation), and radiological imaging (like X-rays) at defined intervals to assess healing and spinal stability. The primary objective is to determine the overall cure rate at the one-year mark. Additionally, the study will measure secondary outcomes, including changes in pain levels, improvements in daily functional abilities, and the rate of any complications or necessary surgical interventions.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients presenting to Assiut University Hospital and its affiliated outpatient clinics with clinical symptoms and/or radiological findings suggestive of primary pyogenic (bacterial) spondylodiscitis, regardless of age or sex. Exclusion Criteria: * Patients with postoperative or iatrogenic spinal infections (secondary spondylodiscitis following spinal surgery or instrumentation). * Non-pyogenic spondylodiscitis. * Patients with incomplete medical records or insufficient follow-up data. * Patients who decline to provide informed consent.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Percentage of Patients Achieving Definitive Cure

Timeframe: 1 year

Trial details

NCT IDNCT07509983

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-05

View on ClinicalTrials.gov More Primary Spondylodiscitis trials

Plain-language summary

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.